儿童特征对华法林剂量要求的影响
Yousif S Alakeel1,2,3, Abdulraouf M Z Jijeh2,4, Norah S BinSabbar1,2,3
1Department Pharmaceutical Care Services, King Abdulaziz Medical City, Ministry of the National Guard - Health Affairs, Riyadh, Saudi Arabia.
Research and practice in thrombosis and haemostasis
|February 19, 2024
概括
儿童的特点显著影响华法林剂量,年龄和体重影响所需的每日总剂量 (TDD). 然而,这些因素并不能预测国际规范化比率 (INR) 水平超出范围的可能性.
科学领域:
- 儿科药理学 儿科药理学
- 药理动力学 药理动力学
- 临床药房 临床药房
背景情况:
- 儿童的特征会影响华法林的剂量,但缺乏共识.
- 了解这些影响对于儿科患者安全有效的抗凝药至关重要.
研究的目的:
- 研究儿童的人口和临床特征如何影响华法林剂量.
- 为了确定在儿科群体中达到治疗性国际规范化比率 (INR) 所需的华法林剂量.
主要方法:
- 对127名接受华法林治疗的儿童 (3个月至14岁) 进行了回顾性队列研究.
- 分析稳定,治疗性INR所需的每日总剂量 (TDD).
- 纳入标准:华法林处方≥3个月与稳定的INR.
主要成果:
- 年龄和体重显著影响了TDD;较小的孩子和身体表面积较低的孩子需要更高的剂量.
- 与正常体重儿童相比,超重和肥胖儿童需要较低的TDD.
- 人口和临床变量没有预测次治疗或超治疗INR值的发生率.
结论:
- 儿科患者的人口统计学因素影响达到目标INR的每日华法林剂量要求.
- 人口因素不能预测国际规范化比率 (INR) 在治疗范围之外的水平的发生.
相关概念视频
Factors Affecting Drug Response: Overview
2.0K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.0K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
697
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
697
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
137
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
137
Drug Dosage Regimen: Overview
3.5K
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
3.5K
Factors Affecting Drug Biotransformation: Biological
149
Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
149


